Surrozen Inc (SRZN) News

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

In a preclinical model of pulmonary fibrosis, a Surrozen antibody-based SWAP platform molecule decreased...

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

-Phase 1a trial demonstrated acceptable safety and tolerability with no reported serious adverse events-Phase...

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

-   $17.5 million upfront proceeds with up to an additional $175 million of proceeds upon the exercise of...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Surrozen Provides Corporate Update on Clinical Programs

Announces strategic prioritization of clinical programs to focus on development of SZN-043 for...

Form 4 - Statement of changes in beneficial ownership of securities

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]